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Introduction
Major injuries incurred from explosive sources in recent military 
interventions have caused high interest in new tissue regenerative 
options. Historically, much progress in plastic surgery techniques for 
burn and trauma management have been during intensive war periods 
[1,2]. Now it is known that many supplementary issues need to be 
addressed before tissue reconstruction including management of pain, 
nutrition, infection, and physiological function. The latter needs to 
be managed by topical biological cover in large surface tissue damage 
to avoid fluid losT. Once available through National Tissue Banks, 
cadaver skin used in the life-saving treatments of burn patients is now 
difficult to access. The first wide use of allogenic cadaver skin was in 
World War II. Alternative sources from humans and animals that are 
conserved frozen or in glycerol are used routinely [3]. Conservation 
techniques using frozen tissues can be appropriate for civilian use 
but could be more difficult for military due to availability of freezers 
on-site. Alternative sources of organs and tissues with their specific 
conservation, along with the development of modern regenerative 
medicine techniques, could help assure quality and security for the 
patient. The possible role of stem cells in military medicine has been 
highly funded by the US Department of Defense (DOD) through the 
Armed Forces Institute of Regenerative Medicine (AFIRM) program 
in past. The recent conflicts in Iraq and Afghanistan have increased the 
intensity of medical research in the military and new DOD proposal 
calls will certainly open many new avenues for cellular therapy.
Cell Therapies used in Military Practice
Many advances in cell therapies have already been made due to 
tax-payer funded research through the AFIRM program to develop 
new treatments using cell therapies and advanced plastic surgery. 
Already in 1997, the DOD awarded 224.7 million dollars to develop 
cell banked sources of bone marrow derived stem cells (BM-MSC) to 
study radiation sickness in collaboration with Osiris Therapeutics and 
Genzyme (www.osiris.com; www.genzyme.com). The same source 
of cells was to be used also for meniscus cartilage regeneration at 
that time. The cell therapy was based on adult donors (18-30 years) 
of bone marrow where cells were isolated by density gradient and 
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Health issues for severe burns and trauma affecting populations from both civilian and military can have many 
similarities. Much of the medical progress for treatment and surgical care has been documented during times of 
catastrophic events and war. Death and morbidity of military personnel due to blast and combat-related injuries has 
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purified by adhesion to eliminate non-MSC cell sources. The cultured 
resulting cells from one donor were to make a stock of 10,000 doses 
of final product called Prochymal® to counter nuclear terrorism and 
other radiological incidents. How the cells are cultured will ultimately 
affect how they will perform. Unfortunately, in the early study with 
these stocked BM-MSC’s, the cells were expanded over numerous 
passages that may have made the cells lose their effectiveness from over 
manipulation. The use of this product in many clinical studies on Graft 
vs. Host Disease has not shown positive significant clinical results but 
this may be also related to patient populations chosen [4-6].
These cells are being investigated for clinical results in other 
diseases (GvHD, Crohn’s disease, cardiology, diabetes, pulmonary 
disease, multiple sclerosis, acute organ rejection, scleroderma and 
arthritis) by Osiris [7]. The DOD and AFIRM have recently awarded 
a grant in Miami this year (http://med.miami.edu/news/miller-school-
physician-scientists-receive-3-million-defense-grant-to-treat/) to 
conduct the first clinical trials on burns and wounds with the BM-
MSC cells and to also look at combined surgical laser techniques with 
the stem cells in third degree burn scar treatments and management. 
In optimizing the cell culture procedure (learning from that of the 
past experience with Prochymal®), these allogenic cell sources could 
possibly be interesting for treating burns and wounds to have readily 
available stocks of frozen cells.
In 2008, AFIRM awarded top hospitals and universities ~300 
million dollars to develop new treatments using cell science and 
advanced plastic surgery which have included research on many 
musculoskeletal tissues (i.e. skin, muscle, cartilage, bone and tendon). 
Massachusetts General Hospital has been developing bioengineered 
ears for soldiers that have lost this appendage in combat. They used 
covered in collagen and the patient’s own cartilage cells that have been 
harvested from either the nose oSribs to seed into the ear scaffold and 
Dr. Sundback has mentioned how amazing progress has been possible 
due to AFIRM funding [10,11]. Other developments are biological 
scaffolds to help patients cells integrate into new tissue formation. 
Extracellular matrix derived from pig intestine has been developed to 
prepare muscle grafts in both former military troops and non-military 
patients [12].
AFIRM is also at the lead to bring foreign developed techniques for 
direct use in clinical trials in the USA. Efforts to make enough skin for 
severe burns have been shown to be possible in a technique developed 
in Australia with a special sprayer device and kit that allows to take a 
2-4 cm skin biopsy from the patient and process it in the operating 
room directly within less than one hour and then to apply the patient 
cells by spraying onto burns and wounds [13,14]. Alternatively, 
foreskin tissue from circumcision has been assessed with this device 
to provide off-the-shelf cell sources ready for use. In a recent clinical 
study program, foreskin tissue cells which have been immortalized 
have been used for burns and wounds. These cells are bioengineered 
to make fresh artificial skin which has been compared to cryopreserved 
cadaver skin for traumatic wound cover and has been shown to be well-
tolerated in the clinic [15]. Importantly, these transformed cells near 
diploid keratinocytes have been shown to be pathogen-free, consistent 
and do not form tumors even though they spontaneously mutated. 
Other clinical trials that are funded by the DOD are concentrated 
adipose tissue and stem cells for restoring facial features in craniofacial 
trauma [16]. Many autologous and now allogenic cell therapies are 
being intensively investigated particularly for musculoskeletal tissue 
regeneration and new techniques to stabilize end-products such as 
freezing and lyophlization are being adapted to assist in logistics and to 
have availability on the battle-field.
Cell Types and Choice for Regenerative Medicine
The term stem cell is vast in definition and there are different 
stem cell types which are related to the tissue of origin and stage of 
development (Figure 1). Importantly, technical aspects necessary to 
isolate and direct stem cells to specific cell types eventually desired 
will ultimately decide which cell choices are better adapted for future 
clinical practice.
Embryonic stem cells
Embryonic stem cells are able to create a wide range of cell types, but 
in order to be able to create these different cells they have to be taken at 
an early age of the embryo (around five days after ovum fertilization). 
Five days after ovum impregnation the “blastocyte” is created and 
embryonic stem cells can be obtained (Figure 1). Specifically, these 
embryonic stem cells are “totipotent” until about eight cells and it is only 
afterwards that they become pluripotent which means that they cannot 
develop into another embryo but they can develop in all different types 
of cells (approximately 2 weeks post-fertilization). Taken together, 
these cells are considered as an embryo until about eight weeks after 
fertilization. From that point on, the embryo is designated as a foetus 
and the embryos are controlled under specific regulation for in vitro 
fertilization where in many countries a specific license is required to 
work with embryonic stem cells.
Fetal cells and tissue
At later stages of development (9-12 weeks of gestation), the tissue 
is considered under Transplantation programs as an organ donation 
and under the same regulation for adult stem cells (Figure 1). Fetal 
tissue can be considered to be an organ donation when from a voluntary 
pregnancy interruption and in Switzerland and many countries world-
wide, there is legal availability of this medical procedure with trends 
remaining stable throughout the last two decades [17-19]. In the United 
States, the importance of having access to legal pregnancy interruptions 
has been brought to attention in women’s public health issues recently. 
Other applications that the military is investigating are devices 
that can be used with individualized kits such as for autologous 
transplantation of BM-MSC. By having a centrifuge that is adapted to 
closed-system tubes for blood and bone marrow collection, these could 
be used directly at the site for patient care (www.arteriocyte.com/). 
The autologous platelet gel that is obtained has the intention of use to 
improve skin graft acceptance and adherence with supposed action of 
providing beneficial growth factors and antimicrobial protection for 
graft survival. Although autologous cell therapies are adapted to the 
individual patient, BM procedures are invasive and painful. Other 
platelet rich preparations can be from whole blood instead of bone 
marrow. Platelet enriched Plasma (PRP) is blood plasma that has been 
enriched with platelets through centrifugation and concentration. 
PRP is less invasive and could be used with the kits for on-site patient 
treatment and have been shown to be beneficial in recent clinical 
activity for wound and burn management [8]. In recent clinical work 
with the Dutch Armed Forces, the Australian Defence Force (ADF) has 
been using special cryo-preserved platelets for treatment of patients in 
Afghanistan. This technique was developed over 30 years ago with the 
US Navy and originally used in clinical work during heart surgery. In 
their experience, they had seen that the frozen platelets were linked to 
fewer adverse events, reduced bleeding more rapidly and reduced the 
total amount of blood required for transfusion [9].
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Figure 1: Cell types and cell choices for regenerative medicine.
Cells derived from tissue at the blastocyst stage are embryonic stem cells, totipotent but less than 100 cells to begin cell cultures. At 5-6 weeks of human develop-
ment, the tissue is embryonic fetal and produces embryonic germ which are pluripotent cells and have more cells to begin cell culture (>1000). Organ specific cells 
are derived from 9-16 weeks of human fetal development and these cells have progenitor capacity which is that they cannot easily de-differentiate when the whole 
population is taken into account and there is a high number of cells (>106) for culture establishment. Adult stem cells can be found within all tissue types (from 
9 weeks of gestation on) and these mesenchymal stem cells can be pluripotent. However, only 1 stem cell is found in every 104-105 cells in total specific tissue. 
Common tissues used in cell therapies to create cell lines in cell culture systems are bone marrow, adipose, placenta, amniotic fluid, retina, cornea and skin. Both 
positive (blue box) and negative (red box) factors are given for each specific cell type.
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Figure 2: Organ Donation Program and Cell Bank Development. 
Multiple fields of expertise are necessary to develop a successful platform for Organ Donations including lawyers to interpret regulatory issues of organ donations 
and defined therapeutic tissue and cellular products, biologists to assure the most appropriate cell choice and technical specifications, engineers for delivery and 
tissue engineering design and medical doctors for donor screening, informed consent and appropriate patient application of tissue and cellular products. One single 
organ donation may produce first a Parental Cell Bank (PCB) of primary cells. Tissue from skin (1-2 cm2) or from bone, cartilage, tendon and disc (0.2-0.5 mm3) 
is enough to produce enough cells for further establishment of Master and Working Cell Banks (hundreds of vials each with 10x106 cells) that are frozen in liquid 
nitrogen (-165°C) and can be kept for decades with high stability.  From each of the Master Cell Bank vials, it is possible to make one Working Cell Bank containing 
hundreds of vials. Safety testing can be at each stage of development (patient to cell banking) before making final cell therapy treatments which can be as high 
as 35x109 for any given musculoskeletal tissue.
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As many as one in three women before the age of 45 seek this medical 
service. It has been proposed that abortion be integrated in primary 
care medicine and not only specialized clinics to assure the best health 
care [20].
Even though fetal cells are considered as adult stem cells, there can 
be certain considerations taken into account since this is associated with 
the voluntary interruption of pregnancy and to assure ethical use of 
available tissue donations. A specific platform has begun in Switzerland 
in 2008 for tracing all aspects of fetal tissue donation to assure complete 
transparency and respect of the Swiss laws and European regulations 
for tissue use (Figure 2) [21-28].
Adult stem cells
Adult stem cells can be isolated from blood tissue, bone tissue, 
nervous tissue, adipose tissue, skin, heart, and all other tissues of the 
body (Figure 1) but the donation must not be paid for and the tissue can 
come from either a living or deceased person. The advantage of adult 
stem cells is that neither the destruction of embryos nor a voluntary 
interruption of pregnancy is necessary. Several conditions must be 
filled in order to remove organs, tissues or cells from a deceased and 
only if: i) the person gave her/his consent before her/his death; and ii) 
the death has been determined (with applied local law).
For living donors, some conditions have to be filled in order to 
donate organs, tissues or cells and the person must: i) be over 18 and 
mentally competent; ii) has been informed comprehensively and has 
given free oral and written consent; iii) be free from severe risk for her/
his life or health; and, iv) know that the recipient cannot be treated by 
any other alternative and efficient therapy without comparable benefit. 
In addition, it is imperative that no sample be taken from a person 
who would not be capable of clear consent with exception in some 
conditions and finally the donor must have adequate health insurance.
Foreskin tissue from new-borns is also considered to be an organ 
donation and cellular derivatives as adult stem cells. The foreskin is 
often taken when the person is young and would be treated similar to 
extra operating room excess tissue, and destined to be destroyed once 
taken. Because this tissue contains fibroblasts which could be useful 
for skin regeneration, the oral and written consent from the legal 
representative could be given in order to use the foreskin tissue for 
purpose of research and clinical use [22].
Technical considerations of cell choices 
The possibility to expand tissue in cell culture systems and have 
cell populations that retain original tissue properties has provided 
enormous possibilities in the transplantation and tissue engineering 
field. Cell therapies are not new in medical treatments as bone marrow 
transplantation has been used for therapeutic purposes for over 40 
years. Newer cell therapies, whereby cells can be maintained outside 
the body in cell culture dishes and flasks and expanded to large 
quantities, were first used successfully for skin grafting and aiding the 
severely burned patient [29]. However, cells from the patient can take 
up to several weeks in culture in order to have enough cells for the 
first treatments. Therefore, other cell sources could be of particular 
importance in the management of severe trauma. One of the major 
challenges for assuring that more patients will benefit from cell-based 
as well as their isolation and proliferation. 
Embryonic stem cells, adult and mesenchymal stem cells, and fetal 
progenitor cells can all be expanded in cell culture systems. These cells 
not only differ highly in their development but also in the complexity 
of cell culture and final delivery for the patient. Tissue choices from 
animal and human sources at all ages of development can be evaluated 
with advantages and disadvantages for each final cell type.
Embryonic stem cells that are isolated from early-stage embryo 
(Figure 1) present the particularity of being pluripotent and have 
an advantage over those cells from adult mesenchymal stem cells, 
which can differentiate only into a restricted number of cell lineages. 
However, cultures of both these stem cell types are technically very 
demanding because the amount of tissue to begin with is very low for 
embryonic stem cells (<100 cells ) and isolation of adult mesenchymal 
stem cells from the tissue mass is difficult (only 1 stem cell for every 104-
5 cells in total adult tissue). Maintenance and expansion of stem cells in 
an undifferentiated state require the addition of many specific growth 
factors [30-33] and efficient culture of embryonic stem cells and some 
adult mesenchymal stem cells are not possible without feeder layers 
which are in some part responsible for the inconsistent colony cell 
growth. The necessity to use many exogenous growth factors as well as 
feeder layers to differentiate into specific cellular lineages are limiting 
factors for the scale-up of embryonic and adult stem cell cultures for 
clinical applications. There are other major issues with these stem cell 
types for security as the cells can de-differentiate once placed into an 
in vivo environment and even develop into tumors. Many techniques 
involving cell cloning or encapsulation have been utilized to date for 
assuring delivery of correct cell populations [34].
Unlike stem cells, fetal cells are differentiated cells with high 
expansion (Figures 1 and 2), regeneration and low immunogenic 
properties [31,35-38]. As the fetal cells are already differentiated and 
do not need to be directed, manipulated or altered, the vast number of 
additional growth factors normally necessary are not needed for cell 
culture and expansion. These cells are not known to de-differentiate 
once placed into the in vivo environment since they are originally from 
defined tissues. They produce uniform primary cultures of cells from 
tissue explants without specific cell selection during tissue processing 
[32,33,39-42].
Establishment of cell banks is a crucial step in the process of many 
vaccines, medicinal products or tissue-engineering products and 
therefore the choice of cell-type is extremely important for technical 
and security reasons. Fetal cells, because of their rapid growth and 
stability, are of high value for techniques in isolation of viruses and 
development of many vaccines. Already, in the 1930’s, medical doctors 
and scientists used tissue from voluntary pregnancy interruptions 
using defined tissue-derived cell lines. The Nobel Prize for Medicine 
in 1954 was awarded to American Immunologists who developed the 
polio vaccine based on cultures of human fetal cells. Since this time, 
many other necessary vaccines (rubella, chicken pox, hepatitis A, 
etc.) have been developed with the use of fetal cell lines including two 
primary human diploid cell lines and importantly, these fetal cell lines 
have been kept in frozen cell banks for decades and are still used safely 
today in manufacturing and production of subsequent cell banks [43-
48]. 
A “Cell Bank” is the stocked product of consistent cell cultures that 
are frozen into small vials that withstand long-term freezing in liquid 
nitrogen (-165°C). The very first cells derived from tissue are designated 
as a parental cell bank and then the original organ donation is thus 
no longer necessary for derivative cell line development (Figure 2). 
The initial cell bank is frequently termed the Master Cell Bank (MCB) 
from which each vial can derive a Working Cell Bank (WCB). Whole 
cell bio-processing and adaptable procedures to Good Manufacturing 
therapies in the future will be the optimization of the choice of cell type 
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Processes (GMP) make it possible to develop extensive MCB and WCB 
to facilitate thorough testing of the cells. Once MCB are accomplished, 
WCB can be produced to establish individual batches of treatments 
for high numbers of patients. Further, these cell banks can be tested 
completely for safety regarding sterility, pathogens, and adventitious 
agents and tumorigenicity.
The development of Master Cell Banks from cell sources provides 
a major advantage for the creation of a therapeutic biological agent 
(Figure 2). The least amount of cellular manipulation to provide enough 
cells for an extensive cell bank is also an advantage. It is important to 
mention that Good Manufacturing Practices are imposed to assure 
that cell cultures are not contaminated not only by virus, bacteria or 
molds but also by other cell lines. Even though this may seem difficult 
to imagine, it is more frequent in practice. When one submits a cell 
line into GMP processing, it is mandatory to do isotyping to assure the 
cellular origin [34,49].
Organization of the progenitor cell therapy platform in Swit-
zerland
Already in 1991, the Swiss Government allowed the Fetal 
Transplantation Platform to be registered with the Department of 
Public Health and the program remained as such until 2007 when 
the new directions and Law of Transplantation took effect (Figure 
2). Since 2008, the Fetal Transplantation Platform was accepted for 
the development of “Clinical Grade Tissues for Musculoskeletal 
Bioengineering” and registered with Swissmedic (Federal Program for 
Registration of Human and Veterinary Medicines and Transplants).
This possibility led to the Swiss Fetal Cell Therapy Platform that 
was developed for musculoskeletal tissues including skin, muscle, 
bone, cartilage, tendon and intervertebral disc [19,21,22,42,50-58] 
(Figure 3). Organ donations were available through a defined program 
where tissue from pregnancy interruption was made accessible when 
the mother had to interrupt her pregnancy for medical grounds. Under 
full written and oral informed consent, the mother donor could be 
accepted into the program for organ donation. The mother donor was 
assessed for specific viruses and infections by donating blood at the time 
of her pregnancy interruption and again after three months to assure 
that there was no sero-conversion. This period of time also allowed the 
mother donor to change her mind regarding her participation in the 
program. The tissue that had been donated could be put into primary 
culture immediately in the core facility for whole-cell bioprocessing 
developed in the University Hospital. The cells derived from the 
primary culture provided the parental cell banks necessary to submit 
to current Good Manufacturing Practice (cGMP) production of cell 
banks similar to those processes used in vaccine production since the 
1950’s.
Clinical cell banks have been fully developed for musculoskeletal 
tissues and skin which have allowed for progress in bioengineering of 
specific tissues that can be used for patient treatments. Regenerative 
medicine and techniques for efficient cellular expansion can perhaps 
help with the overall problem of organ donation availability.
A major advantage of the cells in this unique program with 
progenitor fetal cells is that they adapt particularly well to biomaterials 
allowing efficient and simple delivery to the patient (Figure 3). In our 
laboratory and in others, it has been shown that cells from donors 
(neonatal to adult) are not capable of efficient integration into various 
biomaterials and some biomaterials are in fact toxic to the cell. Ng et 
al. [59] have emphasized that physical characteristics of scaffolds, such 
as porosity and mechanical stability, are important for withstanding 
cell contraction forces and assuring a homogenous distribution of cells 
throughout the scaffold. It is true that the scaffold is very important 
for tissue engineering, but the cell type is most probably the limiting 
factor. We have seen that other fetal progenitor cell types adapt well to 
various biomaterials [50,59-61]. Progenitor skin cells have been used 
successfully in the clinic when associated with hemostatic dressings to 
date. This cell type can be easily integrated into these types of dressings 
to make biological bandages. There has been extensive research in the 
military sector for more functional hemostatic dressings to have life-
saving properties [62]. Biocompatibility of the new formulations could 
easily be done with skin progenitor cells for screening purposes and 
also for development of biologically effective bandages. Importantly, 
future bandages could be directed for specific antimicrobial activity 
especially for military use due to the variability of infectious agents in 
different regions such as Acinetobacter Baumanii in Iraq [63,64].
Military implications of cellular therapy are multidimensional. 
A combat medic in a war zone might be equipped with tear-open 
progenitor skin impregnated bandages that can act as a battlefield 
prophylactic even before a full medical assessment is done. At a 
minimum the impregnated bandage can begin to rapidly heal multiple 
small cuts and abrasions that a soldier might have from being some 
distance from an IED while at the same time offering a firewall to 
targeted infectious agents. At a maximum this battlefield dressing can 
act as a topical biologic cover to avoid fluid loss while the injured soldier 
is transported to the rear for treatment. Triage aspects are also critical 
in a military environment. In a large burn casualty event, such as one 
would deal with in a bombing or IED, the field hospital will have more 
time for assessment because the progenitor skin impregnated dressing 
applied by the medic may not have to be immediately removed and its 
function as a topical biologic cover continues. A more careful renewal 
of the bandages might be the only treatment prior to transport to a 
major treatment center such as Landstuhl Regional Medical Center in 
Germany, where US military evacuees are transported to when they 
leave the operating theater.
Stretching the time of criticality for action through immediate 
battlefield application can have a huge impact on saving the lives of 
both soldiers and civilians caught in these horrendous war episodes. 
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Figure 3: Progenitor fetal cell advantages. 
From only one organ donation, stable sources of primary, diploid cells can be 
produced and stocked for long-term use for the clinic.  Musculoskeletal tissues 
from skin, bone, cartilage, muscle, and tendon from only one parental cell bank 
have been shown to be stable, consistent under simplified culture conditions. 
Cells established in specific cell banking procedures are therefore easily 
screened for safety, have immune privilege and are biocompatible with many 
matrixes making them ideal candidates for cell therapy and delivery to patients 
allowing millions of treatments from one cell stock due to the high growth 
potential.
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By developing consistent cell banks with fetal progenitor cells from 
only one organ donation, many of the risk factors can be eliminated for 
bringing safe and effective human cell-based therapies to the bedside.
Recommendations
With proper and efficient use of organs and cells, there can be 
many advances in new medical technology. Administrative policies 
can assure thorough management of essential aspects including 
scientific, ethical, legal, political, financial and regulatory to help 
establish guidelines and strategies to help at each level of development 
where pressures can exist and otherwise create significant barriers. Cell 
therapies are beginning to show great promise in medicine. As we have 
shown, the cell choice is therefore an important factor for simplifying 
the overall technique and bringing therapy rapidly to the patient. Thus, 
progenitor cells with their high expansion, simple culture conditions 
(do not require feeder layers or extensive growth factors for expansion 
which is a major reason for their consistency in scaling out), and low 
immunogenicity properties are ideal for whole-cell bioprocessing 
destined for cell therapy, tissue-engineering, and medicinal products. 
Additionally, they have already been used in safety clinical phase I 
& II studies showing rapid and efficient tissue repair with minimal 
scarring. Delivery systems to afford better stocking and stability will 
be important milestones for biological products such as that recently 
used in Afghanistan [65]. Overall development needs to keep organ 
donations and patient safety a priority to assist physicians with the use 
of these new emerging therapies for patient care.
Bone marrow mesenchymal stem cells, foreskin cells and 
autologous cells are the cells sources widely explored for cellular 
therapies to date with high financing through the DOD. Other cell 
sources that are stable and that can be easily stocked should be given 
the same opportunity to explore full potential. Foreskin cells from new-
borns are an organ donation and are finally being widely used in tissue 
regeneration. Progenitor cells from fetal tissues have been shown to 
have more potent activity, can be stocked from only one single organ 
donation, and therefore more easily screened for security and safety.
Specifically:
- Optimize cell source for out-scaling and stability
- Optimize stocking of cells and central dispatch
- Optimize cell deposits with specific culture conditions for 
Research and Development 
These cell types can be controlled through rigid federally registered 
Programs of Transplantation, can be deposited in Cell Depositories 
for research and merit attention for further development of new cell 
therapies and advanced plastic surgery techniques. 
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